“In light of all the focus on a coronavirus vaccine, most people tend to overlook the other happenings in the industry,” notes the author of today’s article. He reminds us that, even in the midst of a global pandemic, research has continued on treatments and drugs for cancers, genetic diseases, rare diseases and more – and he highlights three biotech…
When it comes to the advantage that emerging coronavirus stocks have over their more established counterparts, the author of today’s article notes that, “While coronavirus vaccine companies such as Moderna, AstraZeneca, and Pfizer have market caps amounting to tens of billions of dollars, small- to mid-cap coronavirus stocks can potentially be multi-baggers, albeit with higher risks.” He proceeds to take…
“With all of the hype about the race to develop coronavirus vaccines, it’s not surprising that short-sellers have piled on some of the stocks of biotechs with COVID-19 vaccine candidates,” acknowledges the author of today’s article. He further points out, however, that “if these companies have good news, there could be a short-squeeze scenario where the stocks skyrocket as short-sellers…
While the Trump administration has not publicly identified the drugmakers and biotechs involved in Operation Warp Speed – its effort to have 300 million doses of a safe and effective COVID-19 vaccine ready by January 2021 – some tiny biotechs have been touting their involvement in the program, sending their stocks soaring. For more, CLICK HERE.
Biotech stocks have been experiencing a healthy bounce, with the largest ETF that tracks the group recently hitting an all-time high following the announcement from Moderna that it was seeing early positive results with its coronavirus vaccine candidate. Some traders are cautioning investors to “tread carefully” when it comes to buying in to biotech stocks at their current levels, however,…